Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNP023 proof-of-concept study in early and intermediate age-related macular degeneration
CTR20220008Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Iptacopan in age-related macular degeneration (AMD), sponsored by Novartis. Started Jul 2023; status: completed.
02
Drugs
Iptacopan
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on CTR20220008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220008.